Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after Egfr-Tki
Jiefei Han,Qiuyi Zhang,Binchao Wang,Qing Zhou,Lixu Yan,Zhou Zhang,Huajun Chen,Jian Su,Zhi Xie,Feiyu Niu,Yi Long Wu,Shannon Chuai,Jinji Yang,Zhong-Yi Dong
DOI: https://doi.org/10.1016/j.jtho.2016.11.224
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e20601 Background: In patients with advanced non–small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutations, EGFR-tyrosine kinase inhibitors (TKIs) are often recommended as first-line treatment due to favorable clinical efficacy. However, acquired resistance inevitably develops after a median progression-free survival (PFS) of 9-14 months. Small cell histologic transformation was reported to account for nearly 5% of acquired resistance. However, the molecular details underlying this histological change and resistance to EGFR-TKI therapy remain unclear. Methods: Among 320 patients with advanced lung adenocarcinoma who underwent re-biopsy after resistance to EGFR-TKI, 14 were confirmed to develop small cell histologic transformation. We analyzed the clinical parameters of these patients by using chi-square test and Kaplan-Meier analysis. To detect gene alterations that may contribute to small-cell lung cancer (SCLC) transformation, next generation sequencing (NGS) was performed on four pairs of matched pre- and post-resistant tissue samples. We further performed NGS on one pair of matched pre- and post-resistant plasma samples to explore the potential mechanism of resistance to EGFR-TKI. Results: The median PFS and overall survival (OS) of SCLC-transformed patients treated with EGFR-TKI compared to those without transformation were 11.9 vs 12.20 months (P= 0.473) and 26.1 vs 25.9 months (P= 0.664), respectively. The pre- and post-trans tissue samples all preserve the same EGFR and TP53 mutation, increased copy number of five genes (EGFR, APCDD, NOTCH4, DAXX and CUL4A) were identified in post-trans tissue samples detected by the NGS. The NGS result on plasma from one post-trans patient showed an EGFR T790M mutation, which is not found in the post-trans tissue sample from the same patient. Conclusions: The PFS and OS to EGFR-TKI in SCLC-transformed patients are equivalent to those without SCLC-transformation. The gene copy number gain might contribute to this kind of transformation. The mechanisms of acquired resistance to TKI could be the emergence of classic drug resistance mutations such as T790M, which is undetectable due to the intra-tumor heterogeneity.